Literature DB >> 31107244

All hands on DEK.

David M Bodine.   

Abstract

In this issue of the JCI, Capitano et al. demonstrate that the secreted form of the DNA-binding chromatin factor DEK regulates hematopoiesis. It is known that DEK can be secreted by macrophages and other cells, but no function has been attached to secreted DEK. Capitano et al. showed that extracellular DEK activates signaling through the CXCL2 receptor, which in turn enhances the proliferation of hematopoietic stem cells and decreases hematopoietic progenitor cell numbers both in vivo and in vitro. These results offer the opportunity to expand transplantable stem cells to improve outcomes in patients undergoing bone marrow transplant.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31107244      PMCID: PMC6546452          DOI: 10.1172/JCI128986

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  11 in total

Review 1.  The DEK protein--an abundant and ubiquitous constituent of mammalian chromatin.

Authors:  Tanja Waldmann; Ingo Scholten; Ferdinand Kappes; Hong Gang Hu; Rolf Knippers
Journal:  Gene       Date:  2004-12-08       Impact factor: 3.688

2.  The DEK nuclear autoantigen is a secreted chemotactic factor.

Authors:  Nirit Mor-Vaknin; Antonello Punturieri; Kajal Sitwala; Neil Faulkner; Maureen Legendre; Michael S Khodadoust; Ferdinand Kappes; Jeffrey H Ruth; Alisa Koch; David Glass; Lilli Petruzzelli; Barbara S Adams; David M Markovitz
Journal:  Mol Cell Biol       Date:  2006-10-09       Impact factor: 4.272

3.  Secreted nuclear protein DEK regulates hematopoiesis through CXCR2 signaling.

Authors:  Maegan L Capitano; Nirit Mor-Vaknin; Anjan K Saha; Scott Cooper; Maureen Legendre; Haihong Guo; Rafael Contreras-Galindo; Ferdinand Kappes; Maureen A Sartor; Christopher T Lee; Xinxin Huang; David M Markovitz; Hal E Broxmeyer
Journal:  J Clin Invest       Date:  2019-05-20       Impact factor: 14.808

4.  The translocation (6;9) (p23;q34) shows consistent rearrangement of two genes and defines a myeloproliferative disorder with specific clinical features.

Authors:  D Soekarman; M von Lindern; S Daenen; B de Jong; C Fonatsch; B Heinze; C Bartram; A Hagemeijer; G Grosveld
Journal:  Blood       Date:  1992-06-01       Impact factor: 22.113

5.  The DEK oncoprotein is a Su(var) that is essential to heterochromatin integrity.

Authors:  Ferdinand Kappes; Tanja Waldmann; Veena Mathew; Jindan Yu; Ling Zhang; Michael S Khodadoust; Arul M Chinnaiyan; Karolin Luger; Sylvia Erhardt; Robert Schneider; David M Markovitz
Journal:  Genes Dev       Date:  2011-04-01       Impact factor: 11.361

6.  Dek-can rearrangement in translocation (6;9)(p23;q34).

Authors:  D Soekarman; M von Lindern; D C van der Plas; L Selleri; C R Bartram; P Martiat; D Culligan; R A Padua; K P Hasper-Voogt; A Hagemeijer
Journal:  Leukemia       Date:  1992-06       Impact factor: 11.528

7.  The translocation (6;9), associated with a specific subtype of acute myeloid leukemia, results in the fusion of two genes, dek and can, and the expression of a chimeric, leukemia-specific dek-can mRNA.

Authors:  M von Lindern; M Fornerod; S van Baal; M Jaegle; T de Wit; A Buijs; G Grosveld
Journal:  Mol Cell Biol       Date:  1992-04       Impact factor: 4.272

8.  DEK is a poly(ADP-ribose) acceptor in apoptosis and mediates resistance to genotoxic stress.

Authors:  F Kappes; J Fahrer; M S Khodadoust; A Tabbert; C Strasser; N Mor-Vaknin; M Moreno-Villanueva; A Bürkle; D M Markovitz; E Ferrando-May
Journal:  Mol Cell Biol       Date:  2008-03-10       Impact factor: 4.272

Review 9.  High-mobility group box 1 protein orchestrates responses to tissue damage via inflammation, innate and adaptive immunity, and tissue repair.

Authors:  Marco E Bianchi; Massimo P Crippa; Angelo A Manfredi; Rosanna Mezzapelle; Patrizia Rovere Querini; Emilie Venereau
Journal:  Immunol Rev       Date:  2017-11       Impact factor: 12.988

10.  High Levels of DEK Autoantibodies in Sera of Patients With Polyarticular Juvenile Idiopathic Arthritis and With Early Disease Flares Following Cessation of Anti-Tumor Necrosis Factor Therapy.

Authors:  Nirit Mor-Vaknin; Miguel Rivas; Maureen Legendre; Smriti Mohan; Ye Yuanfan; Theresa Mau; Anne Johnson; Bin Huang; Lili Zhao; Yukiko Kimura; Steven J Spalding; Paula W Morris; Beth S Gottlieb; Karen Onel; Judyann C Olson; Barbara S Edelheit; Michael Shishov; Lawrence K Jung; Elaine A Cassidy; Sampath Prahalad; Murray H Passo; Timothy Beukelman; Jay Mehta; Edward H Giannini; Barbara S Adams; Daniel J Lovell; David M Markovitz
Journal:  Arthritis Rheumatol       Date:  2018-02-22       Impact factor: 10.995

View more
  1 in total

1.  DEK-targeting aptamer DTA-64 attenuates bronchial EMT-mediated airway remodelling by suppressing TGF-β1/Smad, MAPK and PI3K signalling pathway in asthma.

Authors:  Yilan Song; Zhiguang Wang; Jingzhi Jiang; Yihua Piao; Li Li; Chang Xu; Hongmei Piao; Liangchang Li; Guanghai Yan
Journal:  J Cell Mol Med       Date:  2020-10-30       Impact factor: 5.295

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.